The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
Tóm tắt
Previous studies have shown that bispecific antibodies that target both CD20 and CD22 have in vivo lymphomacidal properties. We developed a CD20-CD22 bispecific antibody (Bs20x22) from anti-CD20 and the anti-CD22 monoclonal antibodies (mAb), rituximab and HB22.7, respectively. Bs20x22 was constructed using standard methods and was shown to specifically bind CD20 and CD22. In vitro cytotoxicity assays showed that Bs20x22 was three times more effective than either parent mAb alone and twice as effective as a combination of both parent mAb used at equimolar concentrations. Bs20x22 was also nearly four times more effective at inducing apoptosis than either mAb alone. Examination of the MAPK and SAPK signaling cascades revealed that Bs20x22 induced significantly more p38 phosphorylation than either mAb alone. In an in vivo human NHL xenograft model, treatment with Bs20x22 resulted in significantly greater tumor shrinkage and improved overall survival when compared to either mAb alone or treatment with a combination of HB22.7 and rituximab. The effect of the initial tumor volume was assessed by comparing the efficacy of Bs20x22 administered before xenografts grew versus treatment of established tumors; significantly, greater efficacy was found when treatment was initiated before tumors could become established.
Tài liệu tham khảo
Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, Mariotto A, Miller B, Feuer E, Altekruse S, Lewis D, Clegg L, Eisner M, Reichman M, Edwards BE (2008) SEER cancer statistics review, 1975–2005. National Cancer Institute, Bethesda, MD
Lindley C (1991) The lymphomas: Hodgkin’s disease and non-Hodgkin’s lymphomas. Am Pharm NS 31:46–51
Schumer ST, Joyce RM (2003) Radioimmunotherapy for Non-Hodgkin’s Lymphoma. Progress Oncol 46–72
Collins-Burow B, Santos ES (2007) Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev Anticancer Ther 7:257–273
Molina A (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med 59:237–250
Tedder TF, Tuscano J, Sato S, Kehrl JH (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 15:481–504
Sato S, Tuscano JM, Inaoki M, Tedder TF (1998) CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 10:287–297
Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH (1999) CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 94:1382–1392
Williamson JM, Grigor I, Smith ME, Holgate CS, O’Brien CJ, Morgan DR, Quirke P, Alison DL, Child JA, Bird CC (1987) Ploidy, proliferative activity, cluster differentiation antigen expression and clinical remission in high-grade non-Hodgkin’s lymphoma. Histopathology 11:1043–1054
Wain SL, Braylan RC, Borowitz MJ (1987) Correlation of monoclonal antibody phenotyping and cellular DNA content in non-Hodgkin’s lymphoma. The Southeastern Cancer Study Group experience. Cancer 60:2403–2411
Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J (2001) Immunotherapy of Non-Hodgkin’s lymphomas. Hematol Am Soc Hematol Educ Program 221–240
Engel P, Nojima Y, Rothstein D, Zhou LJ, Wilson GL, Kehrl JH, Tedder TF (1993) The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150:4719–4732
Engel P, Wagner N, Miller AS, Tedder TF (1995) Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 181:1581–1586
Law CL, Aruffo A, Chandran KA, Doty RT, Clark EA (1995) Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol 155:3368–3376
Tuscano J, Engel P, Tedder TF, Kehrl JH (1996) Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood 87:4723–4730
Tuscano JM, O’Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL (2003) Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 101:3641–3647
Leonard JP, Goldenberg DM (2007) Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26:3704–3713
Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 23:5044–5051
Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM (2008) Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113:2714–2723
Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 24:3880–3886
Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94:2562–2568
Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G (1996) Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 9:299–305
Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M (2003) Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 89:2234–2243
Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098–2103
Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH (2008) Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 111:2211–2219
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (2009) Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 113:6161–6171
O’Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM (2009) Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother 58:2051–2058
Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A (2003) Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9:3982S–3990S
O’Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM (2009) Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother 58:1715–1722
Poe JC, Fujimoto Y, Hasegawa M, Haas KM, Miller AS, Sanford IG, Bock CB, Fujimoto M, Tedder TF (2004) CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol 5:1078–1087
Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH (1996) Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol 26:1246–1252
Stein R, Belisle E, Hansen HJ, Goldenberg DM (1993) Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 37:293–298
Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF (2006) CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol 177:3063–3073